Fortis Healthcare Ltd

- The transcript provided on pages 4-16 of the document does not explicitly mention any current or planned new fundraising through debt or equity. - The balance sheet remains healthy with a net debt to EBITDA ratio of 0.45x as of Q3 FY24, indicating manageable leverage. - There is no mention of raising new capital through equity or additional debt in the near term. - The company is focusing on operational improvements, bed expansions, and divestments but no active fundraising exercises are disclosed. - Private equity investors in Agilus have an exit timeline around April 2024, connected to a potential IPO, but no direct new equity issuance by the company is detailed. - Overall, no explicit plans or announcements of fresh fundraising through debt or equity are described in the current transcript.

- The company has already spent INR 450 crores in capex during the current 9 months, with similar trends expected in the coming quarter. - Investments include state-of-the-art technology such as Gamma Knife, MR-Linac, two Linac replacements, a Da Vinci robotic surgery system, and an orthopedic robot (~INR 5-6 crores). - The focus is on expanding high-end specialties like oncology, neurology, and robotic surgeries to drive ARPOB increases and margin improvements. - Brownfield bed expansions are planned to add nearly 2,200 beds over the next 4 years, with ~350 beds from an acquired hospital (Medeor, Manesar) and other expansions across existing facilities. - New facilities and expansions (e.g., Ludhiana, Manesar, Noida) will be operationalized based on occupancy ramp-up to ensure cost-effective bed addition. - Strategic moves include portfolio rationalization by divesting loss-making facilities to improve overall profitability. - The company maintains margin guidance aiming for 25% EBITDA margin over 3-4 years with these investments.

- Fortis Healthcare plans to add approximately 2,200 beds over the next 4 years, focusing primarily on brownfield expansions within existing hospitals to leverage operational efficiencies. - New facility openings include a 70-bed unit in Ludhiana and bed additions in Mulund, Kolkata, Bangalore, and Manesar, supporting volume growth. - Revenue growth is expected from increased occupancy (currently around 64-67%, with a target to reach ~70% and beyond), and a rising contribution from high-end specialties like oncology, neurosciences, and robotic surgeries. - ARPOB (Average Revenue per Occupied Bed) growth will moderate from previous high levels (~19%) to a sustainable ~5% driven by a growing mix of complex, high-value procedures. - International patient revenue is stabilizing after recent geopolitical impacts and is expected to return to prior levels. - Digital channel revenues grew 32% YoY, indicating growth in digital engagement and revenues from online sources.

- Earnings momentum remains healthy, particularly in the hospital business, with well-defined growth levers such as brownfield expansions, advanced medical programs, and superior patient experience. - Bed expansion plan includes ~2,200 beds over the next 4 years, primarily through brownfield expansions in existing facilities, aiding margin improvement. - EBITDA margin targets: aiming for ~20% margin by year-end; long-term goal to achieve ~25% EBITDA margin over 3-4 years with ramp-up in occupancy and bed utilization. - ARPOB (Average Revenue Per Occupied Bed) growth expected around 5% going forward, driven by high-end specialty cases. - Operational efficiencies and cost optimization efforts are expected to support profitability. - Divestments (e.g., Malar hospital) contribute modestly (~0.5-0.6% margin improvement). - Occupancy anticipated to improve to ~70% in upcoming quarters, supporting margin expansion. - Gradual improvement expected in lower-margin hospitals over 2-3 years.

The provided transcript from Fortis Healthcare's Investors/Analysts Meet on February 8, 2024, does not explicitly mention details about the current or expected order book or pending orders. The discussion primarily focuses on: - Bed capacity expansion plans, including addition of ~2,200 beds with significant brownfield expansions. - Expectation of margin improvement over the next 3-4 years. - Operational updates on hospitals like Faridabad, Ludhiana, and Manesar acquisitions. - Divestment strategy with no immediate active plans apart from a very small hospital. - Capital expenditure of INR 450 crores already spent in 9 months on medical technology upgrades. No references to specific orderbooks or pending orders related to sales or contracts were mentioned in the transcript.